Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01175512
Other study ID # 1U01HL097973-01
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date July 2010
Est. completion date December 2011

Study information

Verified date January 2021
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will develop a measure of endogenous opioid tone that might serve as a biological marker for drive for palatable food. Using a 'naltrexone probe,' the investigators will assess whether individual response to one dose of an opioid receptor antagonist, naltrexone, is related to non-homeostatic eating in non-pregnant women. Hypothesis 1: Naltrexone Response will be related to non-homeostatic eating. Hypothesis 2: Response profiles to the 25 mg dose will be slightly less in magnitude than the 50 mg dose. However, responses will be similarly related to non-homeostatic eating measures. Hypothesis 3: Response to naltrexone will be highly stable within individuals across time, in the absence of an intervention.


Description:

Opioid tone may provide a way to identify people at risk of reward based eating, with more accuracy than self-report measures. Knowing such risk could improve treatment matching, and provide a biomarker to assess treatment progress. There is no direct measure of central opioid activity in humans, short of PET scans for opioid receptor binding. However, there is a promising indicator using an opioid antagonist such as naltrexone. Blocking opioid receptor releases the inhibitory opioidergic inputs to hypothalamic corticotropic releasing hormone (CRH) neurons, thus increasing CRH, and eventually cortisol in the blood. The extent of the cortisol rise in response to naltrexone might serve as an indicator of endogenous opioidergic tone. It is hypothesized that greater increases in cortisol indicate weaker endogenous opioid activity (by indicating a more complete opioid blockade). Salivary cortisol response to naltrexone may offer a relatively safe and unobtrusive way to measure endogenous opioidergic tone. We propose to test the reliability and validity of the naltrexone probe, taken at home, as a measure of endogenous opioidergic tone. In a previous study (Daubenmier et al, 2013), we administered a one time 50mg dose of naltrexone and examined nausea and cortisol responses. Results suggested that responses were higher in those who showed greater drive to eat. Here we examine a more direct measure of drive to eat, using the Yale Food Addiction Scale (YFAS), and test whether nausea and cortisol responses were associated with greater drive to eat, whether 50mg produced greater responses than 25 mg, and whether the responses were stable (highly related) when tested again one month later.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria: - Women - Age > 20 to 45 years (pre-menopausal women) - BMI > 30 and no larger than BMI = 40 or 300 pounds Exclusion Criteria: - Inability to provide informed consent or speak English - Needle phobic or fainting in response to blood draw - Diabetes - Currently pregnant or breastfeeding - Currently Smoke - Bulimia (Binge Eating Disorder is common among the obese, and allowed) - Pacemaker - Shift Worker - Beta Blocker Medication use - Liver Medication use - Weight Loss Medication use - Chronic current use of cortisol containing medications - Kidney Disease (based on elevated Blood Urea Nitrogen and Creatinine) - Illegal Drug Use (presence in urine) - Liver Cirrhosis or Acute hepatitis (based on elevated Alanine transaminase) - Substance abuse, mental health, or medical condition that, in the opinion of investigators, will affect study outcomes (e.g., hypertension, severe food allergies).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Naltrexone
4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
Placebo
4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

References & Publications (2)

Daubenmier J, Lustig RH, Hecht FM, Kristeller J, Woolley J, Adam T, Dallman M, Epel E. A new biomarker of hedonic eating? A preliminary investigation of cortisol and nausea responses to acute opioid blockade. Appetite. 2014 Mar;74:92-100. doi: 10.1016/j.appet.2013.11.014. Epub 2013 Nov 27. — View Citation

Gearhardt AN, Corbin WR, Brownell KD. Preliminary validation of the Yale Food Addiction Scale. Appetite. 2009 Apr;52(2):430-6. doi: 10.1016/j.appet.2008.12.003. Epub 2008 Dec 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Ideal Dosage 1) To examine criterion validity by testing whether level of opioid tone (based on response to naltrexone probe) is associated with self reported scores on non-homeostatic eating measures, behavioral and cognitive tasks assessing constructs related to addiction (eg, impulsivity) and ideal dosage (25 vs. 50 mg) in 60 obese women. May 2012
Secondary Test Retest Reliability 2) To examine test-retest reliability of naltrexone response one month later May 2012
Secondary Home Based Measures Reliability 3) To examine the reliability of home based measures. In other words, we will test whether cortisol and nausea responses taken in clinic, which are taken at highly controlled (accurate) times, are comparable to the responses from samples taken at home using saliva measures. May 2012
See also
  Status Clinical Trial Phase
Completed NCT05046938 - Food Addiction and Motivational Interviewing in Nursing Students N/A
Recruiting NCT04192058 - Effect of Transcranial Direct-current Stimulation in Eating Behavior of Women With Fibromyalgia N/A
Recruiting NCT04126239 - Validation of a Food Addiction Screening Test
Completed NCT05649189 - Differences in Length of Telomere in Food Addicted vs Non Food Addicted Persons
Completed NCT04666831 - Adapted Motivational Interviewing and Cognitive Behavioural Therapy for Food Addiction N/A
Completed NCT04218097 - Food Addiction and Follow-up in Subjects With Obesity
Completed NCT04373343 - Food Addiction Clinical Treatment Program N/A
Completed NCT04311450 - Behavioral Weight Loss Treatment for Individuals With Food Addiction N/A
Completed NCT04105712 - The Biobehavioral Impact of Diet Quality on Affect and Craving N/A
Recruiting NCT06387719 - Precursors of Binge Eating Disorder in a Clinical Sample of Adolescents With Obesity
Recruiting NCT06030362 - Probiotic Intervention Study N/A
Recruiting NCT04626570 - Impact of a Phone-based Cognitive and Behavioral Therapy on Food Addiction in Patients With Severe or Morbid Obesity N/A
Recruiting NCT04692909 - Deep Transcranial Magnetic Stimulation (dTMS) of the Medial Prefrontal Cortex in Food Addiction and Obesity N/A
Recruiting NCT05437809 - Biobehavioral Reward Responses Associated With Consumption of Nutritionally Diverse Ultra-Processed Foods N/A
Recruiting NCT06044285 - Ultra Crave: An Investigation of Ultra-Processed Food N/A

External Links